Fraser represents public and private companies in transactional matters including mergers and acquisitions, and debt and equity financings, in addition to general corporate matters. Fraser also counsels public companies in corporate governance and compliance matters. He represents both private companies and investment funds in venture capital and private equity investments, and has advised clients that operate in a variety of industries, including biotechnology, pharmaceuticals, technology and media.
Fraser previously worked as an Associate in the Global Business & Transactions Group at Nixon Peabody LLP, a global law firm. During law school, Fraser interned at Boston Private Financial Holdings, Inc. and the Boston Stock Exchange.
Mergers & Acquisitions
Venture Capital Transactions
- Represented Indevus Pharmaceuticals, Inc. (NASDAQ) in sale to NASDAQ listed buyer for aggregate consideration of up to $600 million
- Represented Fortune 500 global manufacturing conglomerate in multiple buy-side M&A transactions
- Represented manufacturer of plastic containers in sale to private equity backed strategic buyer
- Represented pest control services company in sale to publicly traded strategic buyer
- Represented software provider to the insurance industry in sale to publicly traded strategic buyer in France
- Represented software company in commercial real estate industry in sale to Fortune 500 software provider
- Represented solar energy equipment manufacturer in sale to publicly traded strategic buyer
- Represented private equity fund in multiple acquisitions of document storage companies in a roll-up transaction
- Represented several venture capital funds in investments aggregating in excess of $100 million
- Represented clean tech manufacturer of diesel emission filters in Series A financing
- Represented provider of interactive communication networks to medical professionals in multiple rounds of equity financing
- Represented manufacturer of digital display products in multiple rounds of equity financing
- Represented chemistry materials provider in Series B financing
- Represented EyeGate Pharmaceuticals, Inc. (NASDAQ) in IPO and follow on offering
- Represented Indevus Pharmaceuticals, Inc. (NASDAQ) in $72 million promissory note exchange
- Represented NYSE listed Chinese steel manufacturer in filing of $60 million universal shelf registration statement and subsequent $25 million shelf take-down of common stock and warrants
- Represented NYSE Amex listed mining exploration company in Form 10 spin-off transaction and subsequent $75 million underwritten public offering
- Represented NASDAQ listed manufacturer of armored vehicles for the U.S. military in $152 million and $42 million PIPE transactions
- Represented NASDAQ listed manufacturer of life sciences research systems in $240 million Rule 144A private placement of promissory notes
- J.D., Suffolk University Law School, 2005
- B.A., Boston College, 2001
- Mr. Collin was selected to the Massachusetts Rising Stars list (2013-2015) for Business/Corporate Law.
- Mr. Collin was recognized as a 2016 Emerging Leader in the Dealmaker Category for the M&A Advisor.
3/17/2014, Mergers & Acquisitions Magazine - People Moves of the Week
J. Fraser Collin, Elizabeth Crowley, Christine Fletcher, Sara Decatur Judge, and Jonathan Levi were mentioned in this article by Anthony Noto.
Recent Articles and Publications: